Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

Shots:

  • Alvotech will take care of development and supply of the product while Cipla Gulf, subsidiary of Cipla will be responsible for Alvotech’s AVT02 registration and commercialization
  • The agreement will allow Alvotech to have access for Cipla’s strong commercial network in selected emerging markets enabling patients with high-quality biosimilars
  • Alvotech’s AVT02 is a mAb and a biosimilar to AbbVie’s Humira involved in neutralizing TNF-α targeted for several autoimmune diseases including RA, AS, PP, Psoriatic Arthritis, UC, CD and is currently evaluated in P-III trial with its BLA submission with US FDA and EMA in H1’20

Click here to read full press release/ article | Ref: Cipla | Image: Behance